Nutriband Inc. (NASDAQ: NTRB) announced that Chairman and Co-Founder Serguei Melnik will present at NobleCon21, Noble Capital Markets' annual emerging growth equity conference. The presentation is scheduled for December 3 at 9:30 a.m. Eastern time at Florida Atlantic University's Executive Education Complex in Boca Raton, Florida.
Investors and guests may attend the conference at a discounted rate using code NTRBNOBLECON. For those unable to attend in person, a high-definition webcast will be available the following day at nobleconference.com and Channelchek.com, where it will remain archived for 90 days. The full press release can be viewed at https://nnw.fm/Bx5x3.
Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The company's lead product under development is an abuse-deterrent fentanyl patch incorporating their proprietary AVERSA abuse-deterrent technology. This technology represents a significant advancement in pharmaceutical safety, as it can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The company maintains its corporate website at www.nutriband.com, though the company notes that any material contained in or derived from their websites is not part of the official press release. Additional news and updates relating to NTRB are available in the company's newsroom at https://nnw.fm/NTRB.
This presentation at a major investor conference comes at a critical time for pharmaceutical innovation, particularly in the area of opioid safety. The development of abuse-deterrent technologies like AVERSA addresses a pressing public health concern as opioid abuse continues to pose significant challenges worldwide. Fentanyl, in particular, has been at the center of the opioid crisis, with transdermal patches being vulnerable to misuse through extraction and injection or oral consumption.
The implications of successful abuse-deterrent technology extend beyond investor returns to potentially saving lives and reducing healthcare costs associated with opioid abuse. If Nutriband's technology proves effective, it could set new standards for transdermal drug delivery systems and influence regulatory approaches to opioid prescribing practices. The presentation at NobleCon21 provides investors and industry observers with insight into the progress of this important pharmaceutical safety innovation.
